IASLC TTLC 2022 | What the future holds for antibodies in treating NSCLC

Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, comments on whether antibodies should be moved to earlier lines of therapy in non-small cell lung cancer (NSCLC). Whilst there has been advances in the development of antibodies, especially in antibody-drug conjugates (ADCs), more research is needed to compare them to existing therapies as a monotherapy or in combination with other treatments. In the case of amivantamab, the monoclonal antibody has the potential to be combined with tyrosine kinase inhibitors (TKIs) or chemotherapy. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22).